Literature DB >> 29930800

Molecular functions of SIRPα and its role in cancer.

Shinichiro Takahashi1.   

Abstract

Signal regulatory protein α (SIRPα), also known as cluster of differentiation (CD)172a or Src homology 2 domain-containing phosphatase substrate-1, is a cell surface receptor expressed on myeloid and hematopoietic stem cells and neurons. Accumulating data suggests an important role of SIRPα in cell signaling as a negative regulator of the phosphatidylinositol 3-kinase signaling and mitogen-activated protein kinase pathways. In various cancers, including prostate, breast and liver, as well as astrocytoma and myeloid malignancies, downregulation of SIRPα is frequently observed, resulting in activation of these downstream signaling pathways. In turn, cell proliferation, transformation, migration and invasion may occur. Recently, it has been reported that blocking CD47, an anti-phagocytic signal expressed on tumor cells and an SIRPα ligand, may serve as a promising therapeutic approach, particular for the treatment of acute myeloid leukemia. In the present review, the current findings on SIRPα are summarized, with particular focus on its role in cancer.

Entities:  

Keywords:  acute myeloid leukemia; cancer; cluster of differentiation 47; myeloid malignancies; signal regulatory protein α

Year:  2018        PMID: 29930800      PMCID: PMC6006759          DOI: 10.3892/br.2018.1102

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  44 in total

1.  Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response.

Authors:  Liangping Yuan; Wen-Mei Yu; Zhimin Yuan; Christian C Haudenschild; Cheng-Kui Qu
Journal:  J Biol Chem       Date:  2003-02-19       Impact factor: 5.157

Review 2.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Authors:  Mark P Chao; Irving L Weissman; Ravindra Majeti
Journal:  Curr Opin Immunol       Date:  2012-02-04       Impact factor: 7.486

3.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Authors:  Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

Review 4.  SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.

Authors:  André Veillette; Jun Chen
Journal:  Trends Immunol       Date:  2018-01-11       Impact factor: 16.687

Review 5.  Cancer immunotherapy targeting the CD47/SIRPα axis.

Authors:  Kipp Weiskopf
Journal:  Eur J Cancer       Date:  2017-03-10       Impact factor: 9.162

6.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

7.  Prostate cancer downregulated SIRP-α modulates apoptosis and proliferation through p38-MAPK/NF-κB/COX-2 signaling.

Authors:  Chen Yao; Gang Li; Ming Cai; Yeyong Qian; Liqin Wang; Li Xiao; Friedrich Thaiss; Bingyi Shi
Journal:  Oncol Lett       Date:  2017-04-21       Impact factor: 2.967

8.  Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.

Authors:  Melissa N McCracken; Adriel C Cha; Irving L Weissman
Journal:  Clin Cancer Res       Date:  2015-06-26       Impact factor: 12.531

9.  Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system.

Authors:  Hideki Okazawa; Sei-ichiro Motegi; Naoko Ohyama; Hiroshi Ohnishi; Takeshi Tomizawa; Yoriaki Kaneko; Per-Arne Oldenborg; Osamu Ishikawa; Takashi Matozaki
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

10.  Expression and activation of signal regulatory protein alpha on astrocytomas.

Authors:  Thomas T Chen; Eric J Brown; Eric J Huang; William E Seaman
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

View more
  4 in total

1.  CD47 is associated with the up-regulation of the PD-1 oncogenic signaling pathway.

Authors:  Danzhen Yao; Jinying Xia; Jianhui Li; Jun Xu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

2.  Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.

Authors:  Marilin S Koch; Mykola Zdioruk; Michal O Nowicki; Alec M Griffith; Estuardo Aguilar; Laura K Aguilar; Brian W Guzik; Francesca Barone; Paul P Tak; Ghazaleh Tabatabai; James A Lederer; E Antonio Chiocca; Sean Lawler
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

3.  A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPα).

Authors:  Yoanna V Vladimirova; Marie K Mølmer; Kristian W Antonsen; Niels Møller; Nikolaj Rittig; Marlene C Nielsen; Holger J Møller
Journal:  Biomolecules       Date:  2022-07-04

Review 4.  Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.

Authors:  Wenting Zhang; Qinghua Huang; Weiwei Xiao; Yue Zhao; Jiang Pi; Huan Xu; Hongxia Zhao; Junfa Xu; Colin E Evans; Hua Jin
Journal:  Front Immunol       Date:  2020-01-28       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.